LGVN FY 2024 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+237.4% YoY

Gross Profit

$2M78.8% margin

Operating Income

-$17M-690.7% margin

Net Income

-$16M-667.8% margin

EPS (Diluted)

$-1.07

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$26M

Total Liabilities

$4M

Stockholders' Equity

$22M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$709,000	+237.4%
Gross Profit	$2M	$221,000	+752.5%
Operating Income	-$17M	-$21M	+21.4%
Net Income	-$16M	-$21M	+25.4%